ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Christian Kähler contributed 30 entries already.
Precise parameter control is the foundation for efficient bioprocessing and scale-up. However, identifying the ideal scale-up strategy can be a work-intensive and time-consuming task. Here, the BioFlo 320 bioprocess controller with its innovative Scale Up Assist and other features can help you simplifying your cell culture process and scale up to working volumes of up to 40 L.
Antibody-Drug Conjugates (ADCs) have been transformative in oncology, offering targeted cancer treatments that enhance efficacy while sparing healthy cells. However, the potential of ADCs extends well beyond cancer care. From autoimmune diseases to metabolic disorders, advancements in ADC technology are paving the way for breakthroughs across a range of therapeutic areas. This article explores how ADCs are redefining treatment paradigms and improving patient outcomes in diverse fields of medicine.
Explore the evolving world of GLP-1 receptor agonists in Issue 42 of The Altascientist, featuring insights on their expanding applications, early-phase development, and real-world case studies.
Through a new partnership with VWR, TriLink Biotechnologies has made its catalogue of industry-leading nucleic acid technologies more available in Europe. By improving the ordering process and reducing lead times, this partnership will support early-phase researchers and established commercial clients with cutting-edge mRNA products.
High-Quality HIV Antigens for Cutting-Edge Solutions
Neurodegenerative diseases like Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS) suffer from a scarcity of effective treatments. Current therapies primarily provide symptomatic relief but do not address the underlying pathology, failing to slow or halt disease progression. This underscores the urgent need to identify new therapeutic targets relevant to the pathology of these conditions. Kinases represent highly tractable drug targets, with kinase inhibitors achieving significant success, particularly in oncology. However, their potential in neurodegenerative diseases remains largely unexplored, presenting a promising avenue for future research and therapeutic development.
Dunn Labortechnik presents the new TEERZ device from Applied BioPhysics.
We are witnessing a significant industrial transformation driven by the adoption of digital tools to manage increasing data volumes and automation to streamline workflows. However, inefficiencies in process development and data management continue to pose major challenges. These challenges are magnified by the complexities of scaling biologics production and ensuring consistency across global teams. Digital tools present an opportunity to improve efficiency and enable remote monitoring of your bioreactor cultures. Introducing BioNsight cloud, a true cloud-based software solution for bioprocess monitoring and analysis. It is fully integrated into the Eppendorf bioprocess control software DASware® control 6 and also features DataHowLab, an innovative AI-enabled analytics solution to save time and resources during process development.
Medix Biochemica expands its offering of critical in vitro diagnostics (IVD) raw materials to premium blockers and stabilizers by acquiring CANDOR Bioscience.
Lille hosted the 2024 editions of BioFIT, MedFIT, and MEDigIT, three internationally recognised events dedicated to innovation in Life Sciences, MedTech and Digital Health. These gatherings serve as catalysts for collaboration and progress, each focusing on a specific aspect of the healthcare innovation landscape.